Physician profile
Maria E Arcila
NPI 1760550594
$41,814.56
in general payments reported to CMS, 2019-2025
8 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $2,575 · 2021: $12K · 2022: $3,575 · 2023: $13K · 2024: $69.53 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $3,125 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,591.00 |
| Travel and Lodging | $3,124.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $462.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $13,486.25 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $9,424.06 | 2020-2025 | |
| Biocartis US, INC | $8,394.03 | 2019-2024 | Idylla |
| Merck Sharp & Dohme LLC | $3,270.00 | 2021 | |
| Roche Diagnostics Corporation | $2,900.00 | 2021 | |
| Genzyme Corporation | $2,405.22 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $1,125.00 | 2021 | |
| Janssen Research & Development, LLC | $810.00 | 2023 | Carvykti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Arcila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.